Dermatitis
Long-term dupilumab safe, efficacious in atopic dermatitis
Dupilumab showed continuous efficacy and safety in the long-term treatment of atopic dermatitis, according to a study.
Cendakimab effective, generally safe for moderate to severe atopic dermatitis
Cendakimab was effective and generally safe in the treatment of moderate to severe atopic dermatitis in adults, according to a press release.
Recently published results highlight nemolizumab’s efficacy, safety in atopic dermatitis
New results evaluating the efficacy and safety of nemolizumab for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis were published in The Lancet, Galderma announced in a press release.
UK health authority recommends Ebglyss for atopic dermatitis treatment in England
The National Institute for Health and Care Excellence has recommended Ebglyss for the treatment of moderate to severe atopic dermatitis in the National Health Service England, according to an Almirall press release.
Patch testing for allergic contact dermatitis with subset of allergens lowers costs
Instead of patch testing with all allergens in any given group, using an optimized subset of allergens to test for allergic contact dermatitis can provide a similar level of care at a reduced cost, according to a study.
Global seborrheic dermatitis prevalence greater than previously reported
Seborrheic dermatitis is more prevalent across the world than previously believed, with a global pooled prevalence of 4.38%, according to a comprehensive meta-analysis.
Enrollment completed in phase 2 trial of bempikibart for atopic dermatitis treatment
Enrollment has been completed in a phase 2 clinical trial for the evaluation of bempikibart as a treatment for adults with persistent, moderate to severe atopic dermatitis, Q32 Bio announced in a press release.
FDA approves Zoryve for atopic dermatitis in adults, children
The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.
FDA pens action letter in response to roflumilast cream 0.15% sNDA for atopic dermatitis
The FDA is working to finalize an action letter regarding Arcutis’ supplemental new drug application for roflumilast cream 0.15% indicated for atopic dermatitis, the company announced in a press release.